India and the Pandemic Agreement: Why PABS Will Decide What "Pharmacy of the World" Means

A MANUFACTURER'S INTEREST DRESSED AS A SOUTHERN CAUSE

India's line at the UN High-Level Meeting combined two demands that look contradictory. It wants equity abroad: fair access to vaccines, drugs and technology for poorer countries. It wants sovereignty at home: room for each state to set its own pandemic rules. Read as diplomatic language, that is fence-sitting.

Read as an interest map, it is exactly what a large manufacturer that controls little of the underlying IP would ask for.

What each side is actually protecting The Global North wants the IP regime it already has.

• Its resistance to binding technology-transfer targets protects pharmaceutical companies that hold patents and production know-how.
• The United States went furthest. It rejected the declaration, calling both PABS and WHO's power to declare pandemics a challenge to its national interests.
• That is less an objection to pandemic preparedness than a refusal to let a multilateral body set terms for US industry. Africa wants funding before it takes on obligations.
• African countries refused to commit to monitoring the human-animal-environment interface without significant funding, which the North did not guarantee.
• This is rational. Surveillance commitments without money mean poor health systems take on costs while richer countries benefit from the early warning. India's position sits between the two.
• It is called the pharmacy of the world and has one of the largest shares of vaccine manufacturing by volume.
• But the patents on most vaccines it makes are held by global companies and it relies on imports for APIs.
• India therefore benefits from a regime that pushes technology and licences southwards. It is equally exposed to one that imposes rules on its own manufacturers or health system. Equity abroad and sovereignty at home are two sides of that single interest.

Why

PABS decides India's leverage PABS determines what a country receives for sharing a pathogen sample. If benefit-sharing means real technology transfer and licensing, India's manufacturing capacity becomes the obvious place to produce for the world.

If it means only token donations of finished doses, India stays a contract manufacturer working on others' IP. The weak point is India's own rules. India cannot credibly demand benefit-sharing from the North while its domestic rules on access to biological material and distribution of benefits fall short of that standard. That is CSEP's sharpest point and it is a matter of credibility, not courtesy.

A negotiator asking for reciprocity must show it applies reciprocity at home.

Bridge, not

bloc Leading a Global South bloc would be the obvious role, but it is the wrong one. A bloc hardens the North-South divide, which is the very thing stalling PABS. India's advantage is that it is involved in both groups:

• co-sponsor of Partners for Multilateralism alongside the EU and Canada; - architect of the Global Initiative on Digital Health; - a manufacturer that Northern companies depend on. Its value in the negotiation lies in brokering a PABS that Northern patent-holders will sign and Southern states can trust, not in leading the South against the North.